Raloxifene won't act like estrogen in the uterus and is not linked to an increased chance of uterine most cancers. In order to aid a speedy screening of the synthesized compounds a cell-dependent sEH degradation assay was formulated depending on the HiBiT-technologies. A composition-action-pa